BioVersys

BioVersys, a Swiss biopharmaceutical company spun-off from ETH-Zurich, focuses on the R&D of compounds that switch-off pathogen drug-resistance to restore the effectiveness of antibiotics.In February 2014, BioVersys and SARomics initiated the SARTRIC project to codevelop novel therapeutics against multidrug-resistant bacterial infections.In June 2022, BioVersys AG raised CHF 24.2 million in the first closing of its Series C round.In September 2020, the company announced the completion of a CHF 19 million Series B financing fround.In March 2011, the company raised CHF 2.5 million (US $2.71) in a seed financing round